Clinical Study
Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study
Table 1
Schedule of events for each clinic visit.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aIf not done in the last 30 days or if washout period from prohibited medications is required. bAt week 8, tacrolimus levels will be obtained predose and 1.5 hours after the dose. In the event that a change to a chronic medication is needed, tacrolimus blood levels will be obtained within 7–14 days if the concomitant medication is known to interfere with the metabolism of tacrolimus. cIf necessary, and at any time during the study period. dShould the patient require a longer period to titrate the administration of interferon beta-1b, visit 3 can be delayed until after the patient has been on a full dose of interferon beta-1b for at least 1 month. eIn the event of early discontinuation, MRI will be performed at final visit if patient completed at least 3 months of treatment on the combined therapy. |